IDEXX Laboratories, Inc.$586.12TEVA · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B | $16.66B | $16.89B | $18.27B |
| Cost of Revenue | $8.32B | $8.48B | $8.20B | $7.95B | $8.28B | $8.93B | $9.35B | $9.97B |
| Gross Profit | $8.94B | $8.06B | $7.64B | $6.97B | $7.59B | $7.73B | $7.54B | $8.30B |
| Research & Development | — | — | — | $98.00M | — | — | — | $114.00M |
| Selling, General & Administrative | $1.29B | $1.16B | $1.16B | $1.18B | $1.10B | $1.17B | $1.19B | $1.30B |
| Operating Income | $2.16B | -$303.00M | $433.00M | -$2.20B | $1.72B | -$3.57B | -$443.00M | -$1.64B |
| Interest Expense | $916.00M | $1.00B | $1.03B | $930.00M | $891.00M | $901.00M | $822.00M | $920.00M |
| Other Income / (Expense) | -$934.00M | -$981.00M | -$1.06B | -$966.00M | -$1.06B | -$834.00M | -$822.00M | -$959.00M |
| Income Before Taxes | $1.22B | -$1.28B | -$624.00M | -$3.16B | $658.00M | -$4.41B | -$1.26B | -$2.60B |
| Provision for Income Taxes | -$180.00M | $676.00M | -$7.00M | -$643.00M | $211.00M | -$168.00M | -$278.00M | -$195.00M |
| Net Income | $1.41B | -$1.64B | -$559.00M | -$2.45B | $417.00M | -$3.99B | -$999.00M | -$2.15B |
| Basic EPS | $1.23 | -$1.45 | -$0.50 | -$2.20 | $0.38 | -$3.64 | -$0.91 | -$2.35 |
| Diluted EPS | $1.21 | -$1.45 | -$0.50 | -$2.20 | $0.38 | -$3.64 | -$0.91 | -$2.35 |
| Basic Shares Outstanding | 1.15B | 1.13B | 1.12B | 1.11B | 1.10B | 1.09B | 1.09B | 1.02B |
| Diluted Shares Outstanding | 1.16B | 1.13B | 1.12B | 1.11B | 1.11B | 1.09B | 1.09B | 1.02B |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $1.96 | $1.90 | $2.02 | 4 | ↑0 ↓1 |
| Dec 2027 | $3.03 | $3.00 | $3.06 | 4 | ↑0 ↓1 |
